The United Laboratories International Holdings Limited (HKG:3933)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.06
-1.82 (-14.13%)
At close: Mar 13, 2026
Market Cap21.82B -4.7%
Revenue (ttm)15.45B +0.7%
Net Income3.36B +5.3%
EPS1.85 +5.3%
Shares Out1.97B
PE Ratio5.99
Forward PE7.09
Dividend0.64 (5.75%)
Ex-Dividend DateSep 25, 2025
Volume55,098,200
Average Volume12,409,107
Open12.20
Previous Close12.88
Day's Range11.06 - 12.20
52-Week Range11.02 - 17.98
Beta0.14
RSI35.01
Earnings DateMar 24, 2026

About HKG:3933

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin... [Read more]

Sector Healthcare
Founded 1990
Employees 17,400
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3933
Full Company Profile

Financial Performance

In 2024, HKG:3933's revenue was 13.76 billion, an increase of 0.14% compared to the previous year's 13.74 billion. Earnings were 2.66 billion, a decrease of -1.54%.

Financial numbers in CNY Financial Statements

News

Novo Nordisk, United Laboratories International Announce Positive Topline Data From UBT251 Trial

(RTTNews) - Novo Nordisk A/S (NVO), along with The United Laboratories International Holdings Limited, Tuesday announced topline results from a Chinese phase 2 trial of UBT251, a drug jointly develope...

19 days ago - Nasdaq

Novo Nordisk And United Lab Reports Positive Results From Chinese Phase 2 Trial Of UBT251 In Obesity

(RTTNews) - Novo Nordisk A/S (NVO) and The United Laboratories International Holdings Limited (ULIHF, UNJ.F) on Tuesday announced topline results from a Chinese phase 2 trial evaluating UBT251, jointl...

19 days ago - Nasdaq